Alzheimer's Disease

More than 80,000 Kentuckians aged 65 and older live with an Alzheimer’s diagnosis as reported in the 2025 Alzheimer’s Disease Facts and Figures Report, released by the Alzheimer’s Association last week.

Lecanemab, also known by the brand name Leqembi, is not a cure for Alzheimer’s disease. But research indicates the new medication can significantly slow its progression.

This week’s federal approval of a medication called lecanemab — the brand name for which is Leqembi — represents a watershed moment for treating Alzheimer’s disease.

Harvard University's Daniel Lieberman looks at exercise from an evolutionary point of view, concluding that we evolved to limit our physical activity where possible, saving it for survival activities.